NDAORALTABLET
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
XYZAL ALLERGY 24HR (levocetirizine dihydrochloride) by Sanofi is levocetirizine, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of h 1 receptors. Approved for allergic rhinitis, urticaria. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XYZAL ALLERGY 24HR is an oral tablet containing levocetirizine dihydrochloride, the active S-enantiomer of cetirizine, used to treat allergic rhinitis and urticaria. It works by selectively inhibiting H1 histamine receptors with 2-fold higher affinity than cetirizine, providing 24-hour symptom relief.
Peak
Peak-stage OTC/branded antihistamine with moderate competitive pressure (30); mature brand sustains field and brand management roles but with limited growth upside.
Mechanism of Action
Levocetirizine, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of H 1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. In vitro binding studies revealed that…
Indications (2)
Worked on XYZAL ALLERGY 24HR at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.